Examples of other TAAs that could be used in combination with ERBB2 in targeting breast cancer include melanoma-associated antigen-A4 (MAGE-A4) [56], mesothelin [57], and MUC-1 [27]. This evidence concerns the gene MAGEA4 and breast carcinoma.